OS Therapies Inc’s (NYSE:OSTX) Lock-Up Period Set To Expire Tomorrow

OS Therapies’ (NYSE:OSTX) lock-up period is set to expire on Tuesday, January 28th. OS Therapies had issued 1,600,000 shares in its IPO on August 1st. The total size of the offering was $6,400,000 based on an initial share price of $4.00. After the expiration of OS Therapies’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Wall Street Analyst Weigh In

OSTX has been the topic of several recent analyst reports. Maxim Group lifted their price target on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, January 16th. D. Boral Capital reiterated a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research report on Wednesday, January 15th.

OS Therapies Stock Down 7.9 %

Shares of OS Therapies stock opened at $2.69 on Monday. OS Therapies has a 12 month low of $1.58 and a 12 month high of $7.00. The firm’s fifty day moving average price is $3.37.

Insider Buying and Selling

In other OS Therapies news, major shareholder Shalom Auerbach sold 16,720 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the sale, the insider now directly owns 2,531,211 shares in the company, valued at approximately $17,060,362.14. This trade represents a 0.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Investors Weigh In On OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC bought a new stake in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.